Soleus Capital Master Fund, L.P. 13D and 13G filings for C4 Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 3:30 pm Purchase |
2024-09-30 | 13G | C4 Therapeutics, Inc. CCCC |
Soleus Capital Master Fund, L.P. | 6,603,996 9.400% |
4,048,000 (+158.37%) |
Filing |
| 2024-02-05 10:24 am Purchase |
2024-01-26 | 13G | C4 Therapeutics, Inc. CCCC |
Soleus Capital Master Fund, L.P. | 2,555,996 5.200% |
720,000 (+39.22%) |
Filing |
| 2024-02-02 09:34 am Sale |
2023-12-31 | 13G | C4 Therapeutics, Inc. CCCC |
Soleus Capital Master Fund, L.P. | 1,835,996 3.700% |
-626,024 (-25.43%) |
Filing |
| 2023-04-14 5:07 pm Purchase |
2023-04-13 | 13G | C4 Therapeutics, Inc. CCCC |
Soleus Capital Master Fund, L.P. | 2,462,020 5.000% |
2,462,020 (New Position) |
Filing |